✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Concord Biotech Ltd.

CONCORDBIO

Market Cap
₹19,094 Cr.
P/E
51.38

Concord Biotech Ltd.

  • Concord Biotech
  • Biocon
  • Guj. Themis Biosyn
  • TJI Pharma - API & CRAMS
FAQs on Concord Biotech Ltd. Shareprice

Concord Biotech has given better returns compared to its competitors.
Concord Biotech has grown at ~16.8% over the last 1yrs while peers have grown at a median rate of 10.23%

Concord Biotech is not expensive.
Latest PE of Concord Biotech is 51.38, while 3 year average PE is 58.6.
Also latest EV/EBITDA of Concord Biotech is 37.71 while 3yr average is 43.12.

View FAQ's On Business
Growth Table
  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn
Balance Sheet
  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn
Cash Flow
  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn
Quarterly Results
  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Concord Biotech Ltd. Financials

Balance sheet of Concord Biotech is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Concord Biotech is increasing.
Latest net debt of Concord Biotech is -₹0.8 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹87.79 Crs.

Yes, profit is increasing.
The profit of Concord Biotech is ₹373 Crs for TTM, ₹308 Crs for Mar 2024 and ₹240 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Concord Biotech latest dividend payout ratio is 29.71% and 3yr average dividend payout ratio is 29.1%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech